PHIA Koninklijke Philips N.V.

Philips shareholders approve all proposals at the AGM 2025

Philips shareholders approve all proposals at the AGM 2025

May 8, 2025

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2025, including:



  • The re-appointment of Ms Indra Nooyi and Ms Chua Sock Koong as members of the Supervisory Board.
  • The appointment of Mr Bob White as a new member of the Supervisory Board.
  • The re-appointment of Mr Marnix van Ginneken as member of the Board of Management.
  • The discharge of the members of the Board of Management, and of the members of the Supervisory Board.
  • A full overview of the resolutions taken at the AGM 2025 can be found below.



Feike Sijbesma, Chairman of Philips’ Supervisory Board, said: “On behalf of the Supervisory Board and the Board of Management, I extend our heartfelt thanks to David Pyott for his invaluable counsel over the past decade. We are also delighted to welcome Bob White to the Supervisory Board and are very pleased with the re-appointment of Indra Nooyi and Chua Sock Koong. With our highly knowledgeable and experienced members, our Supervisory Board is well-equipped to advise and support Management as they execute Philips’ strategy.”

Mr Sijbesma added: “Together with my colleagues on the Supervisory Board, we extend our congratulations to Marnix van Ginneken on his re-appointment as a member of Philips’ Board of Management. With his strong leadership, profound understanding of the company, and his extensive international corporate governance experience, he is a tremendous asset to Philips.”

Roy Jakobs, CEO of Royal Philips, said: “I am very pleased with Bob White’s appointment to our Supervisory Board. He is a recognized global business leader with deep expertise in health technology. Philips has benefited greatly from the expertise and contributions of Indra Nooyi and Chua Sock Koong, and we are very happy with their re-appointment. Our CFO Charlotte Hanneman and I look forward to continued successful collaboration with Marnix van Ginneken who has been instrumental to Philips, as we strive to improve health and well-being of people through meaningful innovation.”

All resolutions taken at the AGM 2025:

Agenda item Resolution
3 Annual Report 2024
  • Adoption of the financial statements 2024
  • Adoption of a dividend of EUR 0.85 per common share, in shares or (subject to certain conditions) in cash, against retained earnings
  • Positive advisory vote on the approval of the Remuneration Report 2024
  • Discharge of the members of the Board of Management
  • Discharge of the members of the Supervisory Board
4 Composition of the Board of Management 
  • Appointment of Mr Van Ginneken as member of the Board of Management with effect from May 8, 2025
5 Composition of the Supervisory Board         
  • Re-appointment of Ms Chua as member of the Supervisory Board with effect from May 8, 2025
  • Re-appointment of Ms Nooyi as member of the Supervisory Board with effect from May 8, 2025
  • Appointment of Mr White as member of the Supervisory Board with effect from May 8, 2025
6 Authorization of the Board of Management to issue shares or grant rights to acquire shares and restrict or exclude pre-emption rights
7 Authorization of the Board of Management to acquire shares in the company
8 Cancellation of shares

Further details about the dividend can be found via this , and additional information on the composition of the Board of Management, the Executive Committee and the Supervisory Board can be found . Philips’ 2024 financial statements are included in its Annual Report 2024 that was on February 21, 2025.



For more information about Philips’ AGM 2025, please click on this .

For further information, please contact:

Michael Fuchs

Philips Global External Relations

Tel.:

E-mail:

Dorin Danu

Philips Investor Relations

Tel.:

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachments



EN
08/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation ...

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI December 15, 2025 Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled angio-based FFR technology that delivers rapid, accurate coronary physiology assessment from a single angiogram [1] SpectraWAVE’s technologies have the potential to significantly increase adoption of corona...

 PRESS RELEASE

Philips reiterates timing of 2026 outlook

Philips reiterates timing of 2026 outlook December 4, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the company’s previously communicated schedule. As previously guided, the company expects continued performance improvement with sequential comparable sales growth, expanded margins (despite tariff headwinds) and strong cashflow. The company continues to expect comparative sales growth to accelerate sequentially in 2026 towards mid-single-digit gro...

 PRESS RELEASE

Philips expands commercial availability of world’s first real-time AI-...

Philips expands commercial availability of world’s first real-time AI-enabled light-based 3D navigation solution for image-guided therapy December 1, 2025 Commercial availability expanded across Europe and the United StatesReal-time AI-enabled 3D device visualization powered by light instead of X-ray, improving navigation in complex endovascular proceduresLumiGuide seamlessly integrates with Azurion, Philips’ proven, world-leading image-guided therapy platform designed to drive procedural innovation across clinical domains Amsterdam, the Netherlands and Chicago, USA – (NYSE: PHG, AEX: PH...

 PRESS RELEASE

Philips launches Verida, world’s first detector-based spectral CT powe...

Philips launches Verida, world’s first detector-based spectral CT powered by breakthrough AI, to advance diagnostic precision November 30, 2025 Philips pioneered detector-based spectral CT, which has been widely adopted in clinical routine exams across anatomies, supported by over 800 peer-reviewed publications [1]CE-marked, 510k pending Verida CT [2] integrates AI across the imaging chain, providing superb image quality while accelerating workflow and reducing dose [3, 4] Amsterdam, the Netherlands and Chicago, USA – At RSNA 2025, (NYSE: PHG, AEX: PHIA), a global leader in health techno...

 PRESS RELEASE

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MR...

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MRI platform November 30, 2025 Major technology breakthrough combines advanced AI for clinical insights and accelerated workflow in new premium 3.0T MRI platform [1] Amsterdam, the Netherlands, and Chicago, USA – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled BlueSeal Horizon [1], an entirely new 3.0T MRI innovation platform that includes the industry’s first helium-free 3.0T magnet at . A pivotal advance in MRI innovation, helium-free [2] 3.0T is a major scientific achievement set to have s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch